Fulgent Genetics (MEX:FLGT) Float Percentage Of Total Shares Outstanding : 55.04% (As of Jun. 22, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Fulgent Genetics Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Fulgent Genetics's float shares is 16.47 Mil. Fulgent Genetics's total shares outstanding is 29.92 Mil. Fulgent Genetics's float percentage of total shares outstanding is 55.04%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Fulgent Genetics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Fulgent Genetics's Institutional Ownership is 33.99%.

Fulgent Genetics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Fulgent Genetics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	16.47	/	29.92
	=	55.04%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fulgent Genetics (MEX:FLGT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (MEX:FLGT) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

FLGT:USA 7F0:Germany

Address

4978 Santa Anita Avenue, Temple City, CA, USA, 91780

Website

https://www.fulgentgenetics.com

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.